13/03/2018 20:29:57

Inside Science: Alzheimer's Drug Trials Keep Failing -- It May Be Because We Don't Understand the Disease

WASHINGTON, D.C., March 13, 2018 (GLOBE NEWSWIRE) -- In a new story for Inside Science News Service, Joel Shurkin offers an intimate look at why Alzheimer's research is failing to help patients, including his own wife. Inside Science is an editorially-independent nonprofit journalism venture operated by the American Institute of Physics.

 

Researchers have long believed that Alzheimer's disease symptoms are caused by protein deposits called "amyloid plaques." But the amyloid model may be wrong, writes Shurkin, and that could explain why so many new drugs have failed in clinical trials. Shurkin's wife was a patient in a now-canceled trial, and her story offers a poignant glimpse of the human cost of such failures.

 

Shurkin explains the science that led to the amyloid model, as well as the creeping doubts now rising amongst Alzheimer's researchers. He goes on to describe potential new directions for future research -- research that will be too late for his wife, but perhaps life-saving for others down the road. 

 

####

 

ABOUT INSIDE SCIENCE

Inside Science is an editorially-independent nonprofit science news service run out of the American Institute of Physics and supported by a coalition of underwriters. It produces original breaking news stories, features, essays, illustrations, documentaries, animations and news videos, all of which are procurable for syndication by news organizations or available on our web site. https://www.insidescience.org

 

ABOUT AIP

The American Institute of Physics is an organization of physical science societies, representing scientists, engineers, educators, and students. AIP delivers valuable services and expertise in education and student programs, science communications, government relations, career

AIP Media

American Institute of Physics

301-209-3090

media@aip.org

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Jun
PNDORA
Carnegie´s senste negative udmeldning omkring en lille analyse foretaget blandt nogle franchisetager..
30
16 Jun
PNDORA
Som Pandora aktionær er jeg meget tilfreds med ledelsens indsats og de skabte resultater. Ledelsen l..
21
14 Jun
 
Jeg har et par gange øffet over niveauet herinde i dette debatforum. I første omgang skrev jeg til b..
18
18 Jun
PNDORA
              Jeg har lavet en fuld analyse på Pandora, som er en blanding af en regnskabs-analyse o..
17
16 Jun
VELO
Her er mit bud på begivenheder og dato for disse de næste 200 dage. Det bliver en god jul i år som i..
14
16 Jun
VWS
Nu er det jo Vestas der er mindst ramt af prispres, da de selv presser priser ned, da målet er at vi..
14
16 Jun
VWS
http://globenewswire.com/news-release/2018/06/15/1525456/0/en/Vestas-secures-442-MW-order-from-Xcel-..
13
14 Jun
VELO
Endnu et studie med Envarsus er startet op. Denne gang af Washington University School of Medicine. ..
13
19 Jun
VWS
https://www.vestas.com/en/media/company-news?n=1763161#!NewsView
12
14 Jun
PNDORA
Mange har snart mistet så mange penge på pandora, at de eneste smykker de har råd til at købe til ko..
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE
2
Publishing of Sponda's Half Year Financial Report January - June 2018
3
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
4
BioSolar Signs a Joint Development Agreement with Ferroglobe, the Global Leader in the Supply of Silicon Material
5
Swedish economy remains strong and budget surplus grows

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 June 2018 04:49:12
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-20 05:49:12 - 2018-06-20 04:49:12 - 1000 - Website: OKAY